CC
IDXX icon

Capital Counsel’s Idexx Laboratories IDXX Stock Holding History

Capital Counsel’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-32,500
Closed -$82K – 62
2016
Q2 		$82K Buy
+32,500
New +$2.79M 0.01% 56

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Counsel's IDXX Position: Q1 2026 in Review

Capital Counsel reduced its Idexx Laboratories (IDXX) stake by 1.6% in Q1 2026, selling an estimated $4.39M and leaving 420,195 shares worth $236M. The position accounts for 10.04% of the portfolio, ranked #4.

Capital Counsel first reported a position in IDXX in Q2 2013 and has held it in 52 quarters since. The position peaked at $321M in Q2 2021. 1,312 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Capital Counsel held 420,195 shares of Idexx Laboratories worth $236M as of Q1 2026.
  • Capital Counsel sold 6,848 Idexx Laboratories shares in Q1 2026, an estimated $4.39M.
  • Idexx Laboratories made up 10.04% of Capital Counsel's portfolio in Q1 2026, its #4 holding.
  • Capital Counsel first reported a position in Idexx Laboratories in Q2 2013 and has held it in 52 quarters since.
  • Capital Counsel's Idexx Laboratories position peaked at $321M in Q2 2021.
  • 1,312 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Capital Counsel's 13F filing for Q1 2026, filed 15 May 2026.